Accessibility Menu

Bls Pharmaceuticals(ASX) BLS

Market CapA$210.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-31%
5 Year+182%
1 Year+63%
1 Month+14%
A$0.93
+1.09%
+0.01Today
Bls Pharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.932026-08-26
Bls Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.06%AUD 0.942026-08-19
1 month+14.11%AUD 0.822026-07-27
3 month+19.23%AUD 0.782026-05-28
Year to date+121.43%AUD 0.422025-12-31
1 year+63.16%AUD 0.572025-08-26
3 year+675%AUD 0.122023-08-25
5 year+181.82%AUD 0.332021-08-27
Since inception-30.83%AUD 1.332012-04-10

Bls Pharmaceuticals Financials at a Glance

Market Cap

A$210.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

A$0.04

P/E Ratio

22.66

Dividend

A$0.00

Beta (Volatility)

-0.14 (Low)

Price

A$0.93

Volume

83,677

Open

A$0.92

Previous Close

A$0.93

Daily Range

A$0.92 - A$0.93

52-Week Range

A$0.33 - A$1.10

Estimated Earnings Date

N/A

BLS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bls Pharmaceuticals

BLS Pharmaceuticals Limited is a dynamic company engaged in the research, development, marketing, and distribution of health products. With a focus on specialty business services, BLS Pharmaceuticals operates through three key segments: Wholesale, Plant Based, and Direct Sales.

Products and Services
  • Wholesale segment operates in the USA and Asia
  • Plant Based segment focuses on manufacturing and distribution of plant-based products
  • Direct Sales segment targets markets in Australia and Asia
Growth Outlook
  • Market capitalization stands at approximately AUD 190 million
  • Stock price has fluctuated between AUD 0.33 and AUD 1.1 over the past year
  • Beta of 0.623 indicates lower volatility compared to the overall market
Financial Highlights
  • Recent trading volume averages around 91,025 shares
  • Company has not declared dividends in the last year
  • Current stock price is AUD 0.83, reflecting a recent increase
BLS Pharmaceuticals Limited is positioned to capitalize on the growing demand for health products, particularly in the plant-based sector. The company's diverse operational segments allow it to tap into various markets, enhancing its revenue potential. The recent stock price increase and stable trading volume suggest investor interest, while the relatively low beta indicates a more stable investment compared to the broader market. Overall, BLS Pharmaceuticals presents a compelling opportunity for those interested in the healthcare sector.
AI Generated • Aug 3, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Sam Watson

Website

www.bioxyne.com

Headquarters

Sydney, NSW 2000, AU

BLS Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

65.19%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

4.41%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

A$210.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

229.10M

Volume

83.68K

Avg. Volume

262.88K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Bls Pharmaceuticals Performance Analysis

Bls Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 463,636N/A
20232023-06-30AUD 5,154,4151011.7%
20242024-06-30AUD 9,325,02080.9%
20252025-06-30AUD 28,429,544204.9%
Bls Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.01114.9%
20242024-06-30AUD -0.07377.8%
20252025-06-30AUD 0.02N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

A$210.78MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,668.80+0.00%
^DJIDJI
$53,523.88+0.00%
^IXICNASDAQ
$26,095.16+0.00%
BTCBitcoin
$79,272.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CRECre8 Enterprise
$6.21+1.42%
BITOProShares Trust - ProShares Bitcoin ETF
$10.56-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76-0.04%
NVDANvidia
$210.27-0.01%

Questions About BLS

What is the current price of Bls Pharmaceuticals?

Bls Pharmaceuticals is trading at A$0.93 per share.

What is the 52-week range for Bls Pharmaceuticals?

Over the past 52 weeks, Bls Pharmaceuticals has traded between A$0.33 and A$1.10.

How much debt does Bls Pharmaceuticals have?

As of the most recent reporting period, Bls Pharmaceuticals reported total debt of A$1.53M.

How much cash does Bls Pharmaceuticals have on hand?

Bls Pharmaceuticals reported A$7.67M in cash and cash equivalents in its most recent financial results.

What is Bls Pharmaceuticals’s dividend yield?

Bls Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services